Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Paradigm Biopharmaceuticals Limited

INVESTOR PRESENTATION - Paradigm Biopharmaceuticals Limited

ASX:PAR

Paradigm Biopharmaceuticals Limited

Health

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.

Read more

Market Cap

$560.12m

Price at Close

$2.48

4w avg. Volume

539.65k

4w avg. Turnover

$1.34m

Announcements
announcementt+2 movementdate
  • 39th Annual JP Morgan Healthcare Conference Presentation

    Periodic Reports

  • +5.44%

    12 Jan 2021

+5.44%

12 Jan 2021
  • Paradigm to present at the J.P. Morgan Healthcare Conference

    Company Administration

  • 0.00%

    05 Jan 2021

0.00%

05 Jan 2021
  • R&D Investor Presentation

    Periodic Reports · Market sensitive

  • -2.00%

    20 Dec 2020

-2.00%

20 Dec 2020
  • PARADIGM RECEIVES POSTIVE FEEDBACK FROM FDA TYPE C MEETING

    Progress Report · Market sensitive

  • -1.57%

    17 Dec 2020

-1.57%

17 Dec 2020
  • Cleansing Notice and Appendix 2A

    Issued Capital

  • -1.57%

    17 Dec 2020

-1.57%

17 Dec 2020
  • Initial Director's Interest Notice

    Shareholder Details

  • +1.20%

    15 Dec 2020

+1.20%

15 Dec 2020
  • Paradigm Provides Phase 3 Clinical Trial Update

    Progress Report · Market sensitive

  • +1.20%

    13 Dec 2020

+1.20%

13 Dec 2020
  • Paradigm welcomes Amos Meltzer as Non-Executive Director

    Company Administration

  • -6.69%

    08 Dec 2020

-6.69%

08 Dec 2020
  • Paradigm to Host Inaugural R&D Day

    Company Administration

  • -1.45%

    07 Dec 2020

-1.45%

07 Dec 2020
  • Paradigm to Present at Evercore ISI HealthCONx Conference

    Company Administration

  • +1.67%

    01 Dec 2020

+1.67%

01 Dec 2020
Market Data

Current Price

$2.48

52WK HIGH

$4.5

52WK LOW

$1.08

1YR RETURN

-35.92%

1YR RETURN VS. SECTOR

-73.43%

90 DAY RETURN

-16.22%

ASX RANK

377

/2,047

SECTOR RANK

25

/168

SHARES OUTSTANDING

225.85m
ASX:PAR

Paradigm Biopharmaceuticals Limited

Health

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.

Read more

Market Cap

$560.12m

Price at Close

$2.48

4w avg. Volume

539.65k

4w avg. Turnover

$1.34m

ASX:PAR is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.